The postsurgical combination of capecitabine and oxaliplatin can improve disease-free survival for elderly patients with stage III colorectal cancer, according to new data that will be presented at the American Society of Clinical Oncology's annual gastrointestinal cancer symposium.Though not statistically significant, favorable trends were seen in two age-based subanalyses of a previously reported randomized phase III trial comparing a XELOX regimen of capecitabine (Xeloda) and oxaliplatin (Eloxatin)...